कृपया अन्य खोज का प्रयास करें
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Kapil Dhingra | 65 | 2021 | Non-Executive Chairman |
Karen J. Wilson | 61 | 2021 | Independent Non-Executive Director |
Stephen Allen Hurly | 56 | 2019 | CEO, President & Executive Director |
James Julian Noble | 65 | 2022 | Independent Non-Executive Director |
Andrea van Elsas | 58 | 2018 | Chairman of Advisory Board |
Padmanee Sharma | - | 2020 | Member of Advisory Board |
James Patrick Allison | - | 2020 | Member of Advisory Board |
K. Dane Wittrup | - | - | Member of Advisory Board |
Madhav V. Dhodapkar | - | - | Member of Advisory Board |
Jay Thomas Backstrom | 69 | 2022 | Non-Executive Director |
Dieter Kabelitz | - | - | Member of Advisory Board |
Mary E. Wadlinger | 64 | 2023 | Non-Executive Director |
Christy J. Oliger | 54 | 2023 | Non-Executive Director |
Peter A. Kiener | 72 | 2023 | Non-Executive Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है